CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AMGN

Teprotumumab

Phase 3
Amgen Inc. (AMGN)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Thyroid Eye Disease

View Full Landscape
Drug Information

Target Indication

Thyroid Eye Disease

Clinical Trial

NCT03461211

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA6/19/2025

Tepezza

Treatment of moderate to severe thyroid eye disease (TED).

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.